Efficacy of Pentoxifylline on Chronic Kidney Disease

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To study whether pentoxifylline has additive renoprotective effect in patients taking ARB

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Pentoxifylline

Criteria

Inclusion Criteria:

• Chronic kidney disease with serum creatinine 1.3~6.0 mg/dl

Exclusion Criteria:

• History of allergy to pentoxifylline

• Females are nursing or pregnant

• Obstructive uropathy

• Unable to stop chronic immunosuppressive therapy, NSAID

• Congestive heart failure (New York Heart Association functional class III or IV)

• Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form

• Cerebral hemorrhage within the past 6 months prior to signing the informed consent form

• Retinal hemorrhage within the past 6 months prior to signing the informed consent form

• Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma)

• Severe uncontrolled hypertension with SBP > 220 mmHg and/or DBP > 115 mmHg

• Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST > 2 times the upper limit of the normal range

• Biliary obstructive disorders (e.g. cholestasis)

• Active malignancy